Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
MSD, the Japanese unit of US Merck, hauled in the largest sales among 11 foreign mega pharma companies operating in Japan in FY2020, capturing the top spot in this ranking for the first time, according to a Jiho tally. The…
To read the full story
Related Article
- AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
- Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
- Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
- Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Foreign Drug Makers Seeking to Offset Risk in US, European Markets by Driving Growth in “Attractive” Japanese Market
May 23, 2014
BUSINESS
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
- Six Eisai Executives Took Home Over 100 Million Yen in FY2025
June 16, 2026
- Hisamitsu to Raise Prices on Salonpas, Other OTC Products
June 16, 2026
- Eisai to Invest £48 Million to Build Cold-Chain Capability in UK
June 16, 2026
- Susmed Bags 240 Million Yen Milestone for Tinnitus App
June 16, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…